1. Home
  2. PETZ vs CALC Comparison

PETZ vs CALC Comparison

Compare PETZ & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TDH Holdings Inc.

PETZ

TDH Holdings Inc.

N/A

Current Price

$0.99

Market Cap

10.4M

Sector

Industrials

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.61

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PETZ
CALC
Founded
2002
2011
Country
China
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4M
9.7M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
PETZ
CALC
Price
$0.99
$0.61
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
2.0K
179.0K
Earning Date
04-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.46
52 Week High
$1.68
$7.20

Technical Indicators

Market Signals
Indicator
PETZ
CALC
Relative Strength Index (RSI) 37.44 45.72
Support Level $0.97 $0.50
Resistance Level $1.09 $0.78
Average True Range (ATR) 0.03 0.04
MACD -0.00 0.01
Stochastic Oscillator 25.00 58.42

Price Performance

Historical Comparison
PETZ
CALC

About PETZ TDH Holdings Inc.

TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: